evipedia.ai
← Back

Ibutamoren for Health & Longevity

Evidence Review created on 09/21/2026 using AI4L / Opus 5

Also known as: MK-677, MK-0677, Ibutamoren Mesylate, LUM-201, Nutrobal

Motivation

Ibutamoren (MK-677) is an oral compound that prompts the pituitary gland to release more of the body’s own growth hormone. Interest starts from a simple observation: growth hormone output falls across adult life, and that decline runs alongside muscle loss, poorer sleep, and more body fat. Because ibutamoren amplifies the body’s own release pattern instead of replacing it, it draws attention from people trying to hold on to muscle and function into later life.

Designed in the 1990s, it was tested by its developer in older adults, in people recovering from hip fracture, and in people with dementia, and development stopped after a safety concern surfaced. It has never been approved anywhere, yet it circulates widely as a research chemical and turns up undeclared in products sold as supplements. A company is now testing it again in children who make too little growth hormone.

This review examines what the human trials measured, what they found on body composition, sleep, and metabolic and cardiac safety, and where the evidence stops. It also sets out the protocols in use, the monitoring they imply, and the open question of whether raising growth hormone signalling helps or hinders a long life.

Benefits - Risks - Protocol - Conclusion

This section lists outside resources that give a high-level overview of ibutamoren, or of growth hormone secretagogues (drugs that prompt the pituitary gland to release more of the body’s own growth hormone), the class it belongs to; systematic reviews (structured surveys of every study addressing one question) and meta-analyses (statistical poolings of those studies) are held back for their own section below.

Three of the six priority platforms carry usable material. Searches of chriskresser.com and lifeextension.com returned nothing on ibutamoren or on growth hormone secretagogues, and lifespan.io carried no article on the compound — only research-news items on blocking the ghrelin receptor in mice, which give no overview of it — so none of the three is represented. Five sources qualified, so the list is not padded.

Grokipedia

  • Ibutamoren

    A long, heavily referenced entry covering the chemistry, absorption and clearance, trial history, gray-market use, adverse effects and regulatory status, useful as an orientation map before the primary trials.

Examine

  • Ibutamoren

    A short, evidence-graded page reaching a blunt verdict: no demonstrated benefit outside growth hormone deficiency, and concern about heart problems in older adults. Written and fact-checked by named reviewers.

ConsumerLab

No ConsumerLab article on ibutamoren exists. A direct site search returns only Recalls & Warnings notices in which ibutamoren appears as an undeclared or illegal ingredient of third-party products, among them a 2025 recall of two children’s growth formulas after regulatory testing found ibutamoren in them; none of these is an article about the compound. Ibutamoren is an unapproved investigational drug rather than a dietary ingredient, and ConsumerLab tests and reviews marketed supplements, so a compound that cannot legally be sold as a supplement falls outside its review scope.

Systematic Reviews

Ibutamoren’s central trade-off is lean tissue and sleep quality set against blood-sugar control and a cardiac safety signal, and neither side of that trade-off is represented in this literature: no systematic review or meta-analysis exists for the claimed benefits, and none exists for the principal risks either.

No systematic reviews or meta-analyses for Ibutamoren were found on PubMed as of 21 September 2026.

Mechanism of Action

Ibutamoren is a non-peptide agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a, the receptor that normally binds ghrelin, the stomach-derived hunger hormone). Binding activates the phospholipase C pathway (a signalling route that releases calcium held inside the cell), exciting the pituitary cells that make growth hormone and neurons of the hypothalamic appetite centre. It amplifies existing growth hormone pulses rather than replacing them: pulse height and troughs rise, pulse number does not (Chapman et al., 1996). Cryo-electron microscopy places it in the same receptor pocket as ghrelin (Liu et al., 2021). The released growth hormone drives liver output of insulin-like growth factor 1 (IGF-1, the circulating signal carrying most of growth hormone’s tissue-building effect) and of its carrier, IGF-binding protein 3.

Key pharmacological properties: oral administration, peak blood levels at one to two hours, a reported terminal half-life near 24 hours, preclinical oral bioavailability above 60%, selectivity for GHSR-1a over the growth-hormone-releasing-hormone receptor, distribution into pituitary and hypothalamic tissue sufficient for the appetite and deep-sleep effects, hepatic metabolism mainly by CYP3A4 (a liver enzyme that clears many prescription drugs), and biliary-faecal elimination.

Two mechanistic readings compete. One treats the age-related fall in growth hormone as a deficit worth correcting. The other holds that reduced growth hormone and IGF-1 signalling is itself a longevity mechanism, so restoring it buys tissue at the cost of later risk. Almost all human pharmacology comes from trials sponsored by Merck, the developer, which had a direct financial interest in its adoption.

Historical Context & Evolution

Ibutamoren came out of a medicinal-chemistry programme at Merck that set out to convert the injectable growth-hormone-releasing peptides of the 1980s into an orally active small molecule. The compound, then L-163,191 or MK-0677, reached human testing by the mid-1990s. Its intended uses were clinical, not recreational: growth hormone deficiency, the muscle wasting of serious illness, frailty and sarcopenia (age-related loss of muscle mass and strength), and functional recovery after hip fracture.

The findings themselves were consistent and mostly modest. Fourteen to 28 days of dosing raised 24-hour growth hormone and restored IGF-1 to young-adult concentrations in healthy older people (Chapman et al., 1996). A week of dosing reversed the nitrogen loss of severe caloric restriction (Murphy et al., 1998). Two months in men with obesity raised fat-free mass and energy expenditure without reducing fat (Svensson et al., 1998). In hip-fracture recovery, IGF-1 rose 84% while functional measures did not separate from placebo (Bach et al., 2004).

Two later results redirected the programme. A 563-patient dementia trial raised IGF-1 by 73% and changed no cognitive or functional outcome (Sevigny et al., 2008), and a second hip-fracture trial stopped early over congestive heart failure cases (Adunsky et al., 2011). Merck, the sponsor of that work, exited. Both readings remain live: orphan designation followed in 2017, Lumos Pharma now runs phase 3 trials as LUM-201, and gray-market use grew from the same body-composition data.

Expected Benefits

High 🟩 🟩 🟩

Sustained Increase in Growth Hormone and IGF-1 Output

Daily oral dosing raises 24-hour growth hormone output and, through it, liver production of IGF-1. In healthy adults aged 64 to 81, 25 mg daily nearly doubled mean 24-hour growth hormone and returned IGF-1 to the young-adult range (Chapman et al., 1996); the rise persisted across two years (Nass et al., 2008) and reappeared in fracture, dementia and dialysis populations. Both assays are clinically validated. This is target engagement, replicated in several randomised trials, not itself a clinical outcome.

Magnitude: Mean 24-hour growth hormone +97% and IGF-1 from 141 to 265 µg/L over four weeks at 25 mg daily; +60% at six weeks and +73% at 12 months in the dementia trial (Sevigny et al., 2008).

Increase in Fat-Free Mass

Fat-free mass rises on treatment, measured by dual-energy X-ray absorptiometry and by four-compartment modelling. Over 12 months in healthy older adults it fell in the placebo group and rose on drug; over eight weeks in men with obesity it rose while total and visceral fat did not fall (Nass et al., 2008, Svensson et al., 1998). The important limitation is that in the 12-month trial the added lean tissue produced no change in machine-measured strength or physical function.

Magnitude: +1.1 kg fat-free mass versus −0.5 kg on placebo at 12 months (between-group P < 0.001, P being the probability that a difference this large would arise by chance alone), alongside +2.7 kg versus +0.8 kg total body weight.

Medium 🟩 🟩

Improved Sleep Quality

Bedtime dosing changes sleep architecture in the direction that ageing erodes: more stage IV deep sleep and more rapid-eye-movement sleep (the dreaming stage), with fewer departures from normal sleep patterns on polysomnography (overnight sleep-laboratory recording). The proposed mechanism is central ghrelin-receptor activation rather than sedation. The evidence is a single small crossover trial covering a young cohort and an older cohort separately (Copinschi et al., 1997), which is why this sits at Medium despite the size of the effect.

Magnitude: In young adults, stage IV duration roughly +50% and rapid-eye-movement sleep more than +20%; in older adults, rapid-eye-movement sleep nearly +50% with shortened time to first such episode.

Protection of Lean Tissue During Caloric Restriction

During a 14-day diet of 18 kcal/kg per day, healthy volunteers lost nitrogen steadily; adding the drug in week two moved nitrogen balance from clearly negative to slightly positive, an effect consistent with the growth hormone rise sparing muscle protein while energy intake stays low (Murphy et al., 1998). This is directly relevant to anyone dieting hard, but it rests on one controlled crossover study in eight young participants and on a biochemical rather than a functional endpoint. The same logic under appetite-suppressing weight-loss drugs is untested (NCT07754045).

Magnitude: Week-two nitrogen balance +0.31 g/day on drug versus −1.48 g/day on placebo (P < 0.01); seven-day integrated balance +2.69 versus −8.97 g·day.

Low 🟩

Reduction in Low-Density Lipoprotein Cholesterol

Twelve months of treatment lowered low-density lipoprotein cholesterol (LDL, the particle fraction carrying most cardiovascular risk) against each participant’s baseline, with no change in total or high-density cholesterol (Nass et al., 2008). The grade is Low: the comparison was within-group, not against placebo, and the change is marginal.

Magnitude: −0.14 mmol/L (−5.4 mg/dL) from baseline at 12 months (P = 0.026), with no significant between-group difference reported.

Faster Functional Recovery After Hip Fracture ⚠️ Conflicted

Two trials asked whether restoring IGF-1 speeds recovery. The larger found no separation despite an 84% IGF-1 rise (Bach et al., 2004); the later one found gait speed improved, most measures not (Adunsky et al., 2011). Net reading: one positive measure amid null results does not establish faster recovery.

Magnitude: Gait-speed score difference 0.7 at 24 weeks (95% confidence interval 0.17 to 1.28, the range within which the true value most likely lies; P = 0.011); stair-climbing power +12.5 W (95% confidence interval −10.95 to 35.88; P = 0.292).

Speculative 🟨

Benefit-Modifying Factors

  • Baseline growth hormone reserve: In adults with childhood-onset growth hormone deficiency, the growth hormone rise was largest in those least deficient at baseline, correlating with both baseline 24-hour growth hormone and baseline IGF-1. A nearly empty pituitary reserve limits what a secretagogue can release.

  • CYP3A4 and CYP3A5 metabolizer status: CYP3A5 (a second liver enzyme clearing the drug alongside CYP3A4) and CYP3A4 both vary by genotype. Reduced-function variants such as CYP3A4*22, and the common non-functional CYP3A5*3, raise exposure from a given dose; extensive metabolizers blunt it.

  • Baseline IGF-1 and adiposity: A low starting IGF-1 leaves the most room for a proportional rise. Obesity independently suppresses growth hormone secretion, which is why the obesity trial produced a smaller relative IGF-1 gain than the healthy-older-adult trials.

  • Sex and oral estrogen use: The 12-month trial deliberately enrolled men, women on hormone replacement and women not on it. Oral estrogens raise first-pass liver load and damp the IGF-1 response to a given growth hormone signal, so transdermal routes preserve more of the effect.

  • Pre-existing conditions: Insulin resistance, type 2 diabetes and prediabetes narrow the usable dose before glucose becomes limiting. Heart failure, active malignancy and untreated obstructive sleep apnoea (repeated breathing pauses during sleep) remove the favourable side of the trade-off altogether.

  • Age within the target range: All the body-composition evidence sits in adults aged 60 and over, where growth hormone output has already fallen. Below about 40 the axis is intact, so the same dose adds proportionally less. Above 75 the cardiac signal dominates.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Reduced Insulin Sensitivity and Rising Fasting Glucose

The most consistent harm. Growth hormone opposes insulin at the liver and in muscle, so glucose drifts up and insulin sensitivity falls. Fasting glucose rose from 5.4 to 6.8 mmol/L over four weeks at 25 mg daily (Chapman et al., 1996); oral glucose tolerance was impaired at two and eight weeks in men with obesity (Svensson et al., 1998); fasting glucose rose and insulin sensitivity fell across 12 months (Nass et al., 2008). Changes are dose-related and reverse on stopping.

Magnitude: +1.4 mmol/L fasting glucose at four weeks in the dose-ranging trial; a smaller +0.3 mmol/L (5 mg/dL) at 12 months with measured loss of insulin sensitivity.

Increased Appetite with Weight Gain

Ghrelin-receptor activation drives hunger directly, which is the same mechanism that produces the benefit in wasting states. In the 12-month trial appetite increase was the most frequent adverse event and body weight rose well beyond the lean-tissue gain, the excess appearing as limb fat and fluid (Nass et al., 2008). Appetite typically subsides over a few months. For anyone managing body composition deliberately, this is the practical reason protocols fail.

Magnitude: Appetite increase in 67% on drug versus 36% on placebo; body weight +2.7 kg versus +0.8 kg at 12 months (P = 0.003), with limb fat +1.1 kg versus +0.24 kg.

Fluid Retention, Peripheral Edema and Musculoskeletal Pain

Growth hormone promotes kidney sodium retention, producing peripheral edema (swelling from fluid pooling in the tissues, typically at the ankles) together with muscle and joint pain and, less often, numbness or tingling from tissue swelling. Reported across the healthy-older-adult trial and the caloric-restriction study (Nass et al., 2008, Murphy et al., 1998). Effects are mild, dose-related, usually transient, and resolve on discontinuation.

Magnitude: Mild transient lower-extremity edema in 44% on drug versus 27% on placebo, and transient muscle pain in 33% versus 9%, across 12 months at 25 mg daily.

Medium 🟥 🟥

Congestive Heart Failure in Frail Older Adults

The single finding that ended clinical development. A phase IIb trial in 123 older hip-fracture patients was terminated early for a congestive heart failure signal, and the authors concluded the drug has an unfavourable safety profile in that population (Adunsky et al., 2011). Fluid retention plus growth-hormone-driven cardiac remodelling is the proposed mechanism. Regulators cite this specific risk when warning against the compound. The signal comes from one trial in a frail population, not from healthy volunteers.

Magnitude: Four congestive heart failure cases on drug versus one on placebo among 123 randomised patients, sufficient to stop the trial before its planned completion.

Modest Prolactin Elevation

The same receptor activation that releases growth hormone also releases prolactin (the pituitary hormone driving milk production, which at high levels suppresses sex-hormone output). Mean prolactin rose about a quarter above baseline while staying inside the reference range in the dose-ranging trial, and peak and integrated prolactin rose in men with obesity, partly attenuating with repeated dosing (Chapman et al., 1996, Svensson et al., 1998). No trial reported gynecomastia (breast tissue growth in men) or breast tenderness.

Magnitude: Prolactin +23% from baseline at 25 mg daily, remaining within the normal reference interval; no clinical consequence was recorded in any trial.

Increased Bone Remodelling Without Density Gain

Growth hormone accelerates both bone formation and bone resorption. Markers of both rose in healthy and functionally impaired older adults and in postmenopausal osteoporotic women (Murphy et al., 1999, Murphy et al., 2001), while the 12-month trial in healthy older adults found no net density gain (Nass et al., 2008). Added to alendronate (an osteoporosis drug that blocks bone breakdown) it raised femoral neck density, but at no other site. The honest reading is a turnover cost with a payoff at one site only, in combination.

Magnitude: Osteocalcin (a bone-formation marker) +22% and urinary N-telopeptide (a bone-resorption marker) +41% against placebo over 12 months at 25 mg daily, with no net bone mineral density gain in healthy older adults; femoral neck density +4.2% versus +2.5% for alendronate alone when the two were combined.

Low 🟥

Elevated Cortisol ⚠️ Conflicted

Cortisol (the main stress hormone) rose modestly over 12 months (Nass et al., 2008) yet was unchanged at four weeks (Chapman et al., 1996) and only transiently affected in men with obesity. Net reading: cortisol is not reliably raised, and where it rises the change is small.

Magnitude: +47 nmol/L (1.7 µg/dL) at 12 months in the one trial reporting a rise (P = 0.020), against no change at four and eight weeks elsewhere.

Drug-Induced Liver Injury

A 2025 case report describes hepatotoxicity (liver injury shown by rising liver enzymes) attributed to unsupervised use (Cobani et al., 2025). Trials did not flag this, so contaminated gray-market product, doses above trial ranges and co-ingested compounds are plausible contributors. The evidence is one uncontrolled report.

Magnitude: Not quantified in available studies. Only a single case report exists, so the literature gives no incidence figure and no exposure-response relationship.

Gynecomastia and Testosterone Suppression with Stacked Use

Reversible gynecomastia with low testosterone followed use of a multi-ingredient performance product containing MK-677 (Chong et al., 2024), and lowered testosterone with worsened lipids followed MK-677 plus an unapproved muscle-building compound (Cardaci et al., 2022). Co-ingested agents are the likelier drivers.

Magnitude: Not quantified in available studies. No controlled trial has measured gynecomastia incidence for this drug given alone, leaving only two case reports of reversible change.

Gastrointestinal Upset, Fatigue and Headache

Diarrhoea, bloating, abdominal pain, fatigue and headache were each logged in a minority of participants over six months at 25 mg daily (NCT05364684); the class review otherwise reports these agents as well tolerated (Sigalos & Pastuszak, 2018). That study was open-label, so none of this separates from background rates.

Magnitude: Over six months at 25 mg daily, fatigue in 3 of 12 participants, diarrhoea, bloating and abdominal pain in 2 of 12 each, and headache in 2 of 12, with no comparator group.

Speculative 🟨

Long-Term Cancer Risk from Sustained IGF-1 Elevation

Higher IGF-1 is associated with colorectal, prostate and breast cancer, and the class review named cancer incidence the outstanding safety question (Sigalos & Pastuszak, 2018). No trial measured cancer; the basis is observational.

Acceleration of Biological Ageing via the Growth Hormone Axis

Low IGF-1 predicts survival among the long-lived (Milman et al., 2014); removing growth hormone receptor signalling in mid-life extends lifespan in mice (Duran-Ortiz et al., 2026). Human data are absent; the basis is mechanistic.

Loss of Effect Through Axis Desensitisation

In rats, prolonged dosing failed to promote growth despite a growth hormone stimulus, linked to rising somatostatin, the brake on growth hormone release (Lee et al., 2018). Human relevance is untested; the basis is animal.

Risk-Modifying Factors

  • Glucose-handling genotype: Diabetes-risk variants in TCF7L2 (a gene governing insulin secretion) and reduced beta-cell reserve make the glucose rise the binding constraint. Variants of GHSR-1a, the target receptor, plausibly alter sensitivity but have not been tested against outcomes.

  • CYP3A4 and CYP3A5 variants: Reduced-function CYP3A4*22 and the non-functional CYP3A5*3 allele slow clearance by these liver enzymes, so a nominal 25 mg behaves like a higher dose and pushes glucose, fluid retention and prolactin further in the same direction.

  • Baseline biomarkers: An HbA1c (a three-month average of blood sugar) at 5.7% or above, or an IGF-1 in the upper third of the age-adjusted range, shortens the margin before harm. Raised NT-proBNP (a heart-strain marker) flags cardiac risk.

  • Sex-based differences: Women on oral estrogen show a damped IGF-1 response, so they sit closer to the side-effect threshold for less benefit. Men carry more of the reported prolactin and testosterone findings, and all published case reports are in men.

  • Pre-existing conditions: Heart failure, prior myocardial infarction (heart attack), active or treated malignancy, diabetes, active retinopathy (retinal damage), obstructive sleep apnoea and cirrhosis each amplify a specific known harm — fluid load, growth signalling, glucose, or impaired clearance.

  • Age within the target range: The heart failure signal arose in frail patients aged 65 and over recovering from fracture, and fluid retention and glucose effects both worsen with age. Above roughly 70, risk climbs faster than the lean-mass benefit.

Key Interactions & Contraindications

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Caution. Blocking the main clearance enzyme raises drug exposure and amplifies glucose elevation, fluid retention and prolactin rise. Mitigation: separate grapefruit intake, or reduce the dose by half while the inhibitor is in use.

  • Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John’s wort): Monitor. Accelerated clearance can abolish the IGF-1 response, producing full exposure to cost with none of the effect. Mitigation: confirm IGF-1 has actually risen before assuming the protocol is working.

  • Insulin and insulin secretagogues (glipizide, glyburide, drugs that make the pancreas release more insulin): Caution. Induced insulin resistance raises insulin requirements and can unmask diabetes, so a stable regimen loses control. Mitigation: daily glucose monitoring through the first month and dose review with the prescriber.

  • Systemic glucocorticoids (prednisone, dexamethasone): Caution. These steroid drugs add their own hyperglycaemia (raised blood sugar) plus sodium and fluid retention, risking both glucose loss of control and worsening edema. Mitigation: defer initiation until any steroid course has finished.

  • Levothyroxine and thyroid hormone: Monitor. Growth hormone accelerates conversion of thyroxine to the active triiodothyronine, which can unmask borderline hypothyroidism (underactive thyroid) or shift an established replacement dose. Mitigation: thyroid-stimulating hormone and free thyroxine at baseline and at three months.

  • Oral estrogens and combined oral contraceptives: Monitor. First-pass liver exposure to oral estrogen blunts the IGF-1 response to a given growth hormone signal. Mitigation: a transdermal estrogen route preserves more of the effect where clinically appropriate.

  • Somatostatin analogues (octreotide, lanreotide): Caution. These suppress growth hormone release at the pituitary and directly oppose the mechanism, nullifying the intervention. Mitigation: no useful workaround; the two are not sensibly combined.

  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) and decongestants (pseudoephedrine): Monitor. Additive sodium and fluid retention worsens edema and blood pressure. Mitigation: prefer topical anti-inflammatories and limit oral use to short courses.

  • Over-the-counter melatonin and sedating antihistamines (diphenhydramine, doxylamine): Monitor. Additive effect on sleep architecture and next-morning sedation, since the drug already deepens sleep. Mitigation: lower or drop the sleep aid rather than the evening dose.

  • Supplemental growth hormone secretagogues (arginine, ornithine, glycine, gamma-aminobutyric acid, alpha-glycerylphosphorylcholine): Caution, additive. Each nudges growth hormone release by a separate route, so stacking pushes IGF-1 higher than intended. Mitigation: drop them, then set the dose against measured IGF-1.

  • Glucose-lowering supplements (berberine, chromium picolinate, myo-inositol, alpha-lipoic acid): Monitor, additive in the helpful direction. These partly offset the induced insulin resistance. Mitigation: useful deliberately, but watch for low blood sugar if any prescription glucose-lowering drug is also in use.

  • Selective androgen receptor modulators and anabolic androgenic steroids (LGD-4033, RAD-140, testosterone — classes that bind the androgen receptor to build muscle): Caution. Published stacked use worsened lipids, raised liver enzymes and suppressed testosterone beyond either agent alone. Mitigation: avoid the combination.

  • Appetite-suppressing weight-loss drugs (semaglutide, tirzepatide): Monitor, opposing. Hunger signalling runs in opposite directions, and the lean-sparing rationale is being tested rather than established. Mitigation: track lean mass and glucose rather than weight alone.

  • Other interventions (resistance training, caloric restriction, rapamycin): Monitor. Resistance training and dieting are the two contexts where the lean-tissue effect matters most; rapamycin pushes growth signalling the other way, so the pairing is mechanistically incoherent.

Populations who should avoid Ibutamoren:

  • Anyone with heart failure of NYHA Class II or above (the New York Heart Association scale, where Class II means symptoms on ordinary activity), reduced ejection fraction, or a raised NT-proBNP
  • Anyone with a myocardial infarction within 90 days, or uncontrolled hypertension above 160/100 mmHg
  • Anyone with active malignancy, or a treated malignancy within five years, given sustained IGF-1 elevation
  • Anyone with diabetes, or prediabetes defined as HbA1c 5.7% or above or fasting glucose 100 mg/dL or above
  • Anyone with active diabetic retinopathy or known proliferative retinopathy
  • Anyone with acromegaly (a disorder of growth hormone excess), an untreated pituitary adenoma (a benign pituitary tumour), or an IGF-1 above the age-adjusted reference range
  • Anyone with hepatic impairment of Child-Pugh Class B or C (a liver-function score in which Class C is severe), or unexplained liver enzyme elevation
  • Anyone pregnant, attempting conception, or breastfeeding
  • Children and adolescents with open growth plates, outside a supervised trial
  • Anyone critically ill or recently post-operative, where high-dose growth hormone raised mortality (Takala et al., 1999)
  • Anyone subject to anti-doping testing, since the compound sits on the World Anti-Doping Agency Prohibited List and the United States Department of Defense prohibited ingredient list

Risk Mitigation Strategies

  • Start at 5–10 mg and titrate slowly: Protocols that begin at 5–10 mg nightly, hold four weeks, then move to 25 mg only if glucose and weight are stable, keep the dose-related insulin resistance, edema and appetite surge tolerable.

  • Set the dose against measured IGF-1, not a label: Holding IGF-1 in the 100–160 ng/mL band, and never above the age-adjusted upper limit, limits the mechanistic cancer and ageing-axis concerns that scale with sustained elevation.

  • Front-load glycaemic surveillance: Fasting glucose, fasting insulin and HbA1c at baseline, week 4, week 12, then quarterly; stopping at HbA1c 5.9% or fasting glucose 100 mg/dL prevents a reversible glucose drift becoming established diabetes.

  • Screen the heart before starting after 60: Blood pressure, NT-proBNP and an echocardiogram where any symptom or edema exists directly address the congestive heart failure signal that ended clinical development in frail older patients.

  • Cycle rather than run continuously: Eight to 12 weeks on followed by four to eight weeks off caps cumulative IGF-1 exposure, lets insulin sensitivity recover, and re-tests whether the effect is still present.

  • Control intake deliberately during the appetite phase: Pre-planned meals, protein at 1.6–2.2 g/kg per day, and weekly weighing counter the appetite-driven fat and fluid gain that otherwise cancels the lean-mass benefit.

  • Hold sodium down and keep resistance training in: Sodium under about 2,300 mg daily plus two to four resistance sessions weekly reduce peripheral edema and give the added lean tissue a mechanical reason to become functional strength.

  • Monitor liver enzymes and avoid stacking: Alanine aminotransferase and gamma-glutamyl transferase (liver enzymes) at baseline, week 12 and twice yearly, with no concurrent selective androgen receptor modulators, addresses the reported liver injury and worsened lipid and testosterone findings.

  • Verify the actual product: An independent laboratory assay of identity and purity on each batch addresses the documented contamination and mislabelling of gray-market material, including products where the compound appeared undeclared.

  • Keep age-appropriate cancer screening current: Colonoscopy, prostate and breast screening on schedule before and during use provides the only practical counterweight to an unquantified risk from years of elevated growth signalling.

Therapeutic Protocol

  • Standard dose: 25 mg administered orally once daily is the dose used in essentially every human trial, from the 1996 dose-ranging study through the 2008 and 2011 trials, and it is the dose at which the IGF-1 effect plateaus.

  • Lower-dose approach: 10 mg daily produced roughly a 57% rise in 24-hour growth hormone against 97% at 25 mg, with proportionally less glucose disturbance. Longevity-oriented practitioners generally favour this end for chronic use.

  • Best time of day: Bedtime dosing is standard. It aligns the amplified pulse with the natural nocturnal growth hormone surge, and the sleep-architecture trial dosed at bedtime, capturing the deep-sleep effect rather than fighting it.

  • Single versus split dosing: Single daily dosing, on the strength of a terminal half-life near 24 hours in humans. Splitting the dose adds daytime appetite and hunger without raising integrated IGF-1, so no trial has used it.

  • Half-life and timing consequence: Peak blood levels at one to two hours, terminal half-life near 24 hours, and pharmacological effect spanning the full day. Steady state arrives within about a week, which is when side effects should be judged.

  • Competing approaches: Recombinant growth hormone injection produces larger effects with loss of pulsatility and feedback; the secretagogue route keeps both but delivers less. Relying instead on resistance training plus protein is the third position; no trial has compared the three.

  • Who popularised each approach: The secretagogue approach came from Merck’s chemistry programme and Michael Thorner’s University of Virginia group; the pediatric route is now Lumos Pharma’s; body-composition use in men with low testosterone was argued from Baylor College of Medicine.

  • Genetic influences on dose: Reduced-function CYP3A4*22 and non-functional CYP3A5*3 slow clearance and argue for starting at 5–10 mg. TCF7L2 diabetes-risk variants argue for tighter glucose ceilings rather than a different dose.

  • Sex-based differences: The 12-month trial enrolled equal numbers of men, women on hormone replacement and women not on it, but was not powered to compare them. Oral estrogen damps the IGF-1 response, so a transdermal route is preferred alongside.

  • Age considerations: All the supporting body-composition evidence is in adults aged 60 to 81. Beyond about 70, and especially with frailty or recent fracture, the cardiac signal argues against the 25 mg dose regardless of tolerability.

  • Baseline biomarkers: A low starting IGF-1 with normal glucose handling supports the full 25 mg. An IGF-1 in the upper reference third, or HbA1c at 5.7% or above, caps the protocol at the low dose or rules it out.

  • Pre-existing conditions that alter response: Obesity suppresses growth hormone output and blunts the relative IGF-1 gain. In dialysis patients IGF-1 rose 65% against placebo while lean mass went unmeasured, so response is documented and benefit is not.

Discontinuation & Cycling

  • Not a lifelong protocol: No trial ran beyond two years and none measured a hard outcome, so indefinite use is unsupported. Practice divides between fixed courses of eight to 12 weeks and continuous use under biomarker control.

  • No withdrawal syndrome: Nothing resembling dependence or rebound has been reported. Growth hormone and IGF-1 return toward baseline within days to weeks as the pituitary resumes its unamplified pulse pattern.

  • Effects are not retained: Appetite normalises, retained fluid is lost, and body weight falls back. In the crossover year the body-composition and hormone changes reversed (Nass et al., 2008), so gains in lean tissue require the exposure to continue.

  • No taper is needed: Because the mechanism amplifies rather than replaces endogenous secretion, feedback control is preserved throughout and abrupt cessation carries no known risk. Tapering has never been studied or required.

  • Case for cycling: Off-periods let insulin sensitivity recover, cap cumulative IGF-1 exposure, and re-test whether the effect is real. Against it, rat data suggest counter-regulation via hypothalamic somatostatin, which cycling would plausibly limit.

  • What to watch on stopping: Glucose and HbA1c should fall back within three months; weight and ankle swelling within weeks. Failure of glucose to recover indicates the exposure unmasked an underlying condition rather than caused one.

Sourcing and Quality

  • No legitimate consumer supply exists: The compound is an unapproved investigational drug, not a dietary ingredient. It cannot legally be sold as a supplement, and the regulator has issued warning letters to companies doing so, so every consumer source is outside the licensed system.

  • Research-chemical labelling is the tell: Material circulates under “Research Facts” panels or “For Research Use Only” wording precisely to sidestep supplement rules. That labelling carries no identity, purity or dose guarantee and no manufacturing oversight.

  • Documented adulteration in both directions: The compound has been found undeclared in marketed products, including a 2025 recall of two children’s growth formulas, and gray-market material is frequently sold alongside or mislabelled as selective androgen receptor modulators.

  • Formulation decides dose accuracy: Material circulates as capsules, loose powder, or a liquid in propylene glycol or ethanol. The liquid depends on dropper technique and degrades with heat and light; powder needs a milligram-accurate scale. Only the mesylate salt has trial data behind it.

  • What to look for: A batch-specific certificate of analysis from an independent laboratory, naming the assay method, reporting identity and purity above 98%, and screening for the androgen-receptor compounds most often co-present. Vendor-supplied certificates without a named laboratory are worthless.

  • Compounding pharmacies are not an alternative: A licensed compounding pharmacy cannot lawfully compound from an unapproved active ingredient, so the usual workaround for off-label peptides does not apply here.

  • The only quality-assured route is a trial: Pharmaceutical-grade material exists as LUM-201 within the sponsor’s clinical programme. Outside that programme, no source carries the identity and purity assurances that the trial supply had.

Practical Considerations

  • Time to effect: Growth hormone and IGF-1 rise within days, and sleep and appetite change almost immediately. Fat-free mass differences took six to 12 months to become clear in the trials, so judging the protocol before three months is premature.

  • Common pitfall — treating the biomarker as the result: Every trial raised IGF-1 and most changed no functional outcome. A confirmed IGF-1 rise demonstrates only that the drug reached its target, not that anything worthwhile followed.

  • Common pitfall — letting appetite decide the diet: The appetite effect is strong and the weight gained is largely fluid and fat unless intake is planned in advance, which is the most frequent reason a protocol produces the opposite of its intent.

  • Common pitfall — ignoring glucose until symptoms appear: Insulin sensitivity falls quietly and well before fasting glucose crosses a diagnostic threshold, so protocols without fasting insulin measurement miss the harm while it is still fully reversible.

  • Regulatory status: Unapproved for any indication anywhere; an orphan designation for growth hormone deficiency exists without approval; prescription-only and import-restricted in Australia; prohibited by the World Anti-Doping Agency and by the United States Department of Defense.

  • Who is stating those positions: The Food and Drug Administration, the World Anti-Doping Agency and the Department of Defense are regulators, not membership bodies, so no membership earns revenue from these positions. Merck and Lumos Pharma, by contrast, held or hold the commercial rights.

  • Cost and accessibility: Gray-market material is cheap, tens of dollars monthly, against thousands for recombinant growth hormone. That gap gives insurers and health systems a reason to favour an oral secretagogue, and growth hormone makers a reason to resist, shaping which trials get funded.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Bedtime dosing deepens stage IV sleep and lengthens rapid-eye-movement sleep through ghrelin-receptor activation, and the growth hormone pulse it amplifies is itself sleep-dependent. The caveat runs the other way: a strong hunger signal at bedtime fragments sleep, so protocols pair the evening dose with a protein-containing meal two hours earlier.

  • Nutrition: Direct and bidirectional. The appetite effect makes deliberate intake planning the deciding variable, and the protein-sparing finding came from a controlled low-energy diet, so the lean-tissue benefit is clearest when energy is restricted and protein held at 1.6–2.2 g/kg daily. Because insulin sensitivity falls, low-glycaemic patterns (meals built on slower-releasing carbohydrate) are preferred.

  • Exercise: Indirect and enabling rather than blunting. Nothing suggests interference with hypertrophy, but the 12-month trial showed added lean mass without added strength in participants not on a structured programme, so resistance training two to four times weekly is what plausibly converts tissue into function. Timing relative to dosing is irrelevant given all-day exposure.

  • Stress management: Indirect and mildly unfavourable. Cortisol rose modestly in one long trial and not in two shorter ones, so any effect is small; the larger interaction is that poor stress control and poor sleep both worsen insulin resistance, which is already this drug’s main cost. Nothing here calls for a specific technique over another.

Monitoring Protocol & Defining Success

Baseline testing establishes both whether the protocol is appropriate and what a later change means. Before starting, the panel below is drawn in full, with fasting samples after 12 hours, sex hormones and prolactin taken mid-morning, and blood pressure and body weight recorded under repeatable conditions. A raised NT-proBNP, an IGF-1 already high for age, or prediabetic glucose handling each argue against starting rather than for closer watching. Ongoing monitoring then follows a front-loaded cadence: glucose, insulin and body weight at week 4; the full panel at week 12; then every three months through the first year and every six to 12 months thereafter, with any new swelling, breathlessness or exertional limitation triggering immediate cardiac reassessment rather than a scheduled draw. Success is defined as a confirmed IGF-1 rise inside the age-adjusted range accompanied by lean-mass and strength gains, with glucose, weight and cardiac markers unchanged.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 (insulin-like growth factor 1) 100–160 ng/mL, and never above the age-adjusted upper limit Confirms the drug reached its target and caps overshoot Conventional adult ranges are age-banded and run roughly 60–250 ng/mL; draw at a consistent time of day; pair with IGF-binding protein 3
Fasting glucose 75–86 mg/dL (4.2–4.8 mmol/L) Earliest routine signal of the main metabolic cost Conventional threshold for impaired fasting glucose is 100 mg/dL, well above the functional target; 12-hour fast
HbA1c (glycated haemoglobin, a three-month average of blood sugar) 4.8–5.3% Integrates glucose exposure that spot testing misses Conventional “normal” extends to 5.6%; no fasting needed; falsely low with anaemia or recent blood loss
Fasting insulin with HOMA-IR Insulin 2–5 µIU/mL; HOMA-IR below 1.5 Detects lost insulin sensitivity months before glucose moves HOMA-IR is a calculated index of insulin resistance; conventional laboratory insulin ranges extend far higher, to about 25 µIU/mL; must be drawn fasting together with glucose, since the index is computed from both
ApoB with LDL cholesterol ApoB below 80 mg/dL; LDL cholesterol below 100 mg/dL Tracks whether the small lipid improvement holds or reverses ApoB is apolipoprotein B, one particle per atherogenic lipoprotein; non-fasting sampling is acceptable for it; conventional laboratory ApoB ranges extend far higher, to about 130 mg/dL
ALT and GGT ALT below 25 U/L in men and 20 U/L in women; GGT below 20 U/L Liver injury has been reported with unsupervised use ALT is alanine aminotransferase and GGT gamma-glutamyl transferase, both liver enzymes; conventional upper limits run to about 40–55 U/L; gray-market product contamination is the likelier cause than the drug itself
NT-proBNP (a peptide the heart releases when its walls are stretched) Below 125 pg/mL Directly addresses the congestive heart failure signal Rises with age and falls with obesity; most informative over age 60 or with any new swelling; draw at rest
Prolactin Below 15 ng/mL Modest rises are expected and should stay inside range Conventional laboratory upper limits run higher, to roughly 18 ng/mL in men and 25 ng/mL in women; draw mid-morning, at least an hour after waking, avoiding prior exercise, stress or chest stimulation, all of which raise it
Total testosterone with SHBG Total testosterone 500–900 ng/dL; SHBG 20–50 nmol/L Detects hormonal shifts reported with stacked use SHBG is sex hormone binding globulin, the main carrier protein for testosterone; the conventional total testosterone range runs wider, roughly 300–1000 ng/dL; draw fasting between 7 and 10 a.m.; interpret the two together, since the ratio is more stable than either alone
TSH with free T4 TSH 0.5–2.0 mIU/L; free T4 in the middle of the laboratory range Growth hormone shifts thyroid hormone conversion TSH is thyroid-stimulating hormone and T4 thyroxine; the conventional TSH range extends to about 4.5 mIU/L; pair with free triiodothyronine; avoid biotin supplements for three days before
Blood pressure with body weight Below 120/80 mmHg; weight within 1–2 kg of the starting value Fluid retention shows up here before it is visible Measured at home, seated, same time of day, after five minutes at rest; a weekly weight trend beats single readings

Qualitative markers worth tracking alongside the laboratory panel:

  • Sleep depth and continuity, and whether night-time hunger is interrupting it
  • Appetite intensity and whether food intake still matches the plan
  • Morning ankle swelling, and tightness of rings, watch straps or shoes
  • Joint and muscle discomfort, and any numbness or tingling in hands or feet
  • Training recovery between sessions and measured strength progression on the same lifts
  • Daytime energy, mental clarity, and any new lethargy
  • Breathlessness on exertion or when lying flat, which warrants immediate reassessment

Emerging Research

  • Pediatric growth hormone deficiency, phase 3: A 150-participant randomised placebo-controlled trial of LUM-201, the pharmaceutical form of ibutamoren, with annualised height velocity at 12 months as primary endpoint (NCT06948214). A positive result would make this the first approved oral growth hormone secretagogue.

  • Long-term safety extension: A 150-participant open-label extension following children from the phase 3 programme, with treatment-emergent adverse events as its primary endpoint (NCT07129759). This is the first study designed to generate multi-year safety data on chronic exposure.

  • Muscle preservation during weight-loss drug therapy: A planned 202-participant phase 2 trial pairing LUM-201 with semaglutide in older adults with obesity, with the proportion scoring 7 or below on the Short Physical Performance Battery at week 26 as primary endpoint (NCT07754045).

  • Liver fat: A completed 12-participant phase 2 study measuring intrahepatic lipid content, the percentage of liver tissue that is fat (NCT05364684). Posted registry results show liver fat rose rather than fell against historical controls; a journal report would settle this metabolic endpoint.

  • Evidence that could weaken the case — the longevity axis: Removing growth hormone receptor signalling in mid-life extended healthy lifespan in mice (Duran-Ortiz et al., 2026), and low IGF-1 predicts survival among the exceptionally long-lived (Milman et al., 2014). Both point the opposite way from chronic use.

  • Evidence that could weaken the case — cancer surveillance: The outstanding question named a decade ago, whether years of elevated IGF-1 changes cancer incidence, remains unanswered (Sigalos & Pastuszak, 2018). The phase 3 extension is the first study large and long enough to contribute.

  • Open question — converting tissue into function: No trial has combined the drug with a structured resistance programme, which is the obvious explanation for lean mass rising without strength (Nass et al., 2008). Until that trial exists, the central benefit claim stays untested where it matters.

Conclusion

Ibutamoren does reliably what it was built to do: administered orally once a day, it makes the pituitary gland release more of the body’s own growth hormone, and the downstream growth signal returns to levels typical of young adults. That much has been shown repeatedly. Beyond it, the picture narrows sharply. Lean tissue increases and sleep deepens, but the added tissue did not translate into measurable strength or physical function, and trials in fracture recovery and in dementia found no benefit at all.

The costs are better established than the gains. Blood sugar control worsens, appetite rises enough to undo the body-composition intent unless intake is planned, and fluid retention with aching joints is common. One trial in frail older patients stopped early over heart failure cases, which is why regulators name this compound specifically. Liver injury and hormonal changes appear in case reports, mostly alongside other compounds.

Almost all of the human evidence was produced by the company that developed the drug and by the company now developing it, both with a direct commercial stake; the regulators taking the opposite view are not membership bodies and earn nothing from their position. No structured survey of this literature exists. For someone weighing years of use, the unresolved question is not whether growth hormone can be raised but whether raising it shortens or lengthens a life, and current animal and human longevity data point the other way.

Top - Benefits - Risks - Protocol